Lindbrook Capital, LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 211 filers reported holding DENALI THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 4.43 and the average weighting 0.2%.

Quarter-by-quarter ownership
Lindbrook Capital, LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,931
-74.0%
239
-62.8%
0.00%
-50.0%
Q2 2023$18,945
+81.1%
642
+41.4%
0.00%
+100.0%
Q1 2023$10,460
+5.9%
454
+27.9%
0.00%0.0%
Q4 2022$9,873
+9.7%
355
+28.2%
0.00%
-50.0%
Q3 2022$9,000
+28.6%
277
+24.2%
0.00%
+100.0%
Q2 2022$7,0000.0%223
+9.3%
0.00%0.0%
Q1 2022$7,000
-74.1%
204
-66.6%
0.00%
-75.0%
Q4 2021$27,000
+1250.0%
611
+1697.1%
0.00%
Q1 2021$2,000340.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders